LISTSERV mailing list manager LISTSERV 16.5

Help for SCIENCE-FOR-THE-PEOPLE Archives


SCIENCE-FOR-THE-PEOPLE Archives

SCIENCE-FOR-THE-PEOPLE Archives


SCIENCE-FOR-THE-PEOPLE@LIST.UVM.EDU


View:

Message:

[

First

|

Previous

|

Next

|

Last

]

By Topic:

[

First

|

Previous

|

Next

|

Last

]

By Author:

[

First

|

Previous

|

Next

|

Last

]

Font:

Proportional Font

LISTSERV Archives

LISTSERV Archives

SCIENCE-FOR-THE-PEOPLE Home

SCIENCE-FOR-THE-PEOPLE Home

SCIENCE-FOR-THE-PEOPLE  February 2020

SCIENCE-FOR-THE-PEOPLE February 2020

Subject:

From 2003: SARS and Genetic Engineering?

From:

Mitchel Cohen <[log in to unmask]>

Reply-To:

Science for the People Discussion List <[log in to unmask]>

Date:

Wed, 12 Feb 2020 12:15:15 -0500

Content-Type:

text/plain

Parts/Attachments:

Parts/Attachments

text/plain (322 lines)

Relevant to today's CoronaVirus situation:


 From 2003

The Institute of Science in Society
Science Society Sustainability http://www.i-sis.org.uk
General Enquiries [log in to unmask]
Website/Mailing List [log in to unmask] ISIS
Director [log in to unmask]

SARS and Genetic Engineering?

The complete sequence of the SARS virus is now 
available, confirming it is a new coronavirus 
unrelated to any previously known. Has genetic 
engineering contributed to creating it? Dr. 
Mae-Wan Ho and Prof. Joe Cummins call for an investigation.

The World Health Organisation, which played the 
key role in coordinating the research, formally 
announced on 16 April that a new pathogen, a 
member of the coronavirus family never before 
seen in humans, is the cause of Severe Acute Respiratory Syndrome (SARS).

"The pace of SARS research has been astounding," 
said Dr. David Heymann, Executive Director, WHO 
Communicable Diseases programmes. "Because of an 
extraordinary collaboration among laboratories 
from countries around the world, we now know with certainty what causes SARS."

But there is no sign that the epidemic has run 
its course. By 21 April, at least 3,800 have been 
infected in 25 countries with more than 200 dead. 
The worst hit are China, with 1,814 infected and 
79 dead, Hong Kong, 1,380 infected and 94 dead, 
and Toronto, 306 infected, 14 dead.

A cluster of SARS patients in Hong Kong with 
unusual symptoms has raised fears that the virus 
may be mutating, making the disease more severe. 
According to microbiologist Yuen Kwok-yung, at 
the University of Hong Kong, the 300 patients 
from a SARS hot spot, the Amoy Gardens apartment 
complex, were more seriously ill than other 
patients: three times as likely to suffer early 
diarrhoea, twice as likely to need intensive care 
and less likely to respond to a cocktail of 
anti-viral drugs and steroids. Even the medical 
staff infected by the Amoy Gardens patients were more seriously ill.

John Tam, a microbiologist at the Chinese 
University of Hong Kong studying the gene 
sequences from these and other patients suspects 
a mutation leading to an altered tissue 
preference of the virus, so it can attack the gut as well as the lungs.

The molecular phylogenies published 10 April in 
the New England Journal of Medicine were based on 
small fragments from the polymerase gene (ORF 1b) 
(see Box), and have placed the SARS virus in a 
separate group somewhere between groups 2 and 3. 
However, antibodies to the SARS virus cross react 
with FIPV, HuCV229E and TGEV, all in Group 1. 
Furthermore, the SARS virus can grow in Vero 
green monkey kidney cells, which no other 
coronavirus can, with the exception of porcine 
epidemic diarrhea virus, also in Group 1.

Coronaviruses

Coronaviruses are spherical, enveloped viruses 
infecting numerous species of mammals and birds. 
They contain a set of four essential structural 
proteins: the membrane (M) protein, the small 
envelope (E) protein, the spike (S) glycoprotein, 
and the nucleocapside (N) protein. The N protein 
wraps the RNA genome into a ‘nucleocapsid’ that’s 
surrounded by a lipid membrane containing the S, 
M, and E proteins. The M and E proteins are 
essential and sufficient for viral envelope 
formation. The M protein also interacts with the 
N protein, presumably to assemble the 
nucleocapsid into the virus. Trimers (3 subunits) 
of the S protein form the characteristic spikes 
that protrude from the virus membrane. The spikes 
are responsible for attaching to specific host 
cell receptors and for causing infected cells to fuse together.

The coronavirus genome is a an infectious, 
positive-stranded RNA (a strand that’s directly 
translated into protein) of about 30 kilobases, 
and is the largest of all known RNA viral 
genomes. The beginning two-thirds of the genome 
contain two open reading frames ORFs, 1a and 1b, 
coding for two polyproteins that are cleaved into 
proteins that enable the virus to replicate and 
to transcribe. Downstream of ORF 1b are a number 
of genes that encode the structural and several non-structural proteins.

Known coronaviruses are placed in three groups 
based on similarities in their genomes. Group 1 
contains the porcine epidemic diarrhea virus 
(PEDV), porcine transmissible gastroenteritis 
virus (TGEV), canine coronavirus (CCV), feline 
infectious peritonitis virus (FIPV) and human 
coronovirus 229E (HuCV229E); Group 2 contains the 
avian infectious bronchitis virus (AIBV) and 
turkey coronavirus; while Group 3 contains the 
murine hepatitis virus (MHV) bovine coronavirus 
(BCV), human coronavirus OC43, rat 
sialodacryoadenitis virus, and porcine hemagglutinating encephomyelitis virus.

Where does the SARS virus come from? The obvious 
answer is recombination, which can readily occur 
when two strains of viruses infect a cell at the 
same time. But neither of the two progenitor 
strains is known, says Luis Enjuanes from the 
Universidad Autonoma in Madrid, Spain, one of the 
world leaders in the genetic manipulation of coronaviruses.

Although parts of the sequence appeared most 
similar to the bovine coronavirus (BCV) and the 
avian infectious bronchitis virus (AIBV) (see 
"Bio-Terrorism & SARS", this series), the rest of 
the genome appear quite different.

Could genetic engineering have contributed 
inadvertently to creating the SARS virus? This 
point was not even considered by the expert 
coronavirologists called in to help handle the 
crisis, now being feted and woed by 
pharmaceutical companies eager to develop vaccines.

A research team in Genomics Sciences Centre in 
Vancouver, Canada, has sequenced the entire virus 
and posted it online 12 April. The sequence 
information should now be used to investigate the 
possibility that genetic engineering may have 
contributed to creating the SARS virus.

If the SARS virus has arisen through recombined 
from a number of different viruses, then 
different parts of it would show divergent 
phylogenetic relationships. These relationships 
could be obscured somewhat by the random errors 
that an extensively manipulated sequence would 
accumulate, as the enzymes used in genetic 
manipulation, such as reverse transcriptase and 
other polymerases are well-known to introduce 
random errors, but the telltale signs would still 
be a mosaic of conflicting phylogenetic 
relationships, from which its history of 
recombination may be reconstructed. This could 
then be compared with the kinds of genetic 
manipulations that have been carried out in the 
different laboratories around the world, 
preferably with the recombinants held in the laboratories.

Luis Enjuanes’ group succeeded in engineering 
porcine transmissible gastroenteritis virus, 
TGEV, as an infectious bacterial artificial 
chromosome, a procedure that transformed the 
virus from one that replicates in the cytoplasm 
to effectively a new virus that replicates in the 
cell nucleus. Their results also showed that the 
spike protein (see Box) is sufficient to 
determine its disease-causing ability, accounting 
for how a pig respiratory coronavirus emerged 
from the TEGV in Europe and the US in the early 
1980s. This was reviewed in an earlier ISIS 
report entitled, "Genetic engineering 
super-viruses" (ISIS News 9/10, 2000), which gave 
one of the first warnings about genetic engineering experiments like these.

The same research group has just reported 
engineering the TGEV into a gene expression 
vector that still caused disease, albeit in a 
milder form, and is intending to develop vaccines 
and even human gene therapy vectors based on the virus.

Coronaviruses have been subjected to increasing 
genetic manipulation since the late 1990s, when 
P.S. Masters used RNA recombination to introduce 
changes into the genome of mouse hepatitis virus 
(MHV). Since then, infectious cDNA clones of 
transmissible TGEV, human coronavirus (HuCV), 
AIBV and MHV have all been obtained.

In the latest experiment reported by Peter 
Rottier’s group in University of Utrecht, The 
Netherlands, recombinants were made of the feline 
infectious peritonitis virus (FIPV) that causes 
an invariably lethal infection in cats. The 
method depends on generating an interspecies 
chimeric FIPV, designated mFIPV, in which, part 
of its spike protein has been substituted with 
that from mouse virus, MHV, as a result, the 
mFIPV infects mouse cells but not cat cells. When 
synthetic RNA carrying the wild-type FIPV S gene 
is introduced into mFIPV-infected cells, 
recombinant viruses that have regained the wild 
type FIPV S gene will be able to grow in cat 
cells, and can hence be selected. So any mutant 
gene downstream of the site of recombination, 
between ORF 1a and ORF1b (see Box), can be 
successfully introduced into the FIPV.

This method was previously used to introduce 
directed mutations into MHV, and like the 
experiment just described, was carried out to 
determine the precise role of different genes in 
causing disease. This targeted recombination is 
referred to as ‘reverse genetics’, and depends on 
the virus having a very narrow host range 
determined by the spike protein in its coat.

Another research team headed by P. Britten based 
in the Institute of Animal Health, Compton 
Laboratory, in the United Kingdom, has been 
manipulating AIBV, also in order to create 
vectors for modifying coronavirus genomes by 
targeted recombination, a project funded by the 
UK Ministry of Agriculture, Fisheries and Food 
and the Biotechnology and Biological Sciences 
Research Council (BBSRC). The procedure involved 
infecting Vero cells, a green monkey kidney cell 
line with recombinant fowlpox virus (rFPV-T7) - 
carrying an RNA polymerase from the T7 
bacteriophage, with a promoter from the vaccinia 
virus - together with AIBV, and a construct of a 
defective AIBV genome in rFPV that can be 
replicated in Vero cells. Recombinant 
cornonaviruses with defective AIBV genomes were 
recovered from the monkey cells. This is 
significant because almost no natural 
coronaviruses are able to replicate in Vero 
cells; the researchers have created a defective 
virus that can do so, when a helper virus is 
present. The defective virus has the potential to 
regain lost functions by recombination.

In addition to the experiments described, the 
gene for the TGEV spike protein has been 
engineered into and propagated in tobacco plants, 
and Prodigene, a company specializing in crop 
biopharmaceuticals, has produced an edible 
vaccine for TGEV in maize. Information on whether 
or not that product was the one being field 
tested in a recent case of contamination reported 
by the USDA was withheld under ‘commercial confidentiality’.

Sources & References

"Coronavirus never before seen in humans is the 
cause of SARS. Unprecedented collaboration 
identifies new pathogen in record time" WHO Press 
Release, 16 April 2003, Geneva [log in to unmask] 
BBC Radio 4 News Report, 19-21 April 2003.
"China says Sars outbreak is 10 times worse than 
admitted" by John Gittings and Jame Meikle, The Guardian 21 April 2003.
"Chinese cover-up creates new sense of 
insecuirity in face of Sars epidemic" by John 
Gittings, The Guardian 21 April 2003.
"SARS virus is mutating, fear doctors" by Debora 
MacKenzie, 16 April 2003, NewScientist.com news service.
Ksiazeh TC, Erdman D, Goldsmith C et al. A novel 
coronavirus associated with severe acute 
respiratory syndrome. NEJM online www.nejm.org 10 April, 2003.
Drosten C, Gunther S, Preiser W et al. 
Identification of a novel coronavirus in patients 
with acute respiratory syndrome. NEJM online www.nejm.org 10 April, 2003.
"Calling all coronavirologists" by Martin Enserik, Science 18 April 2003.
Lai MMC. The making of infectious viral RNA: No 
size limit in sight. PNAS 2000: 97: 5025-7.
Almazan F, Gonsalex JM, Penzes Z, Izeta , Calvo 
E, Plana-Duran J and Enjuanes. Engineering the 
largest RNA virus genome as an infectious 
bacterial artificial chromosome. PNAS 2000: 97: 5516-21.
Ho MW. Genetic engineering super-viruses. ISIS 
News 9/10 , July 2001, ISSN: 1474-1547 (print), ISSN: 1474-1814 (online).
Sola I, Alonso S, Zúñiga S, Balasch M, 
Plana-Durán J and Enjuanes L. Engineering the 
transmissible gasteroenteritis virus genome as an 
expression vector inducing lactogenic immunity. J. Virol. 2003, 77, 4357-69.
Masters PS. Reverse genetics of the largest RNA 
viruses. Adv. Virus Res. 1999, 53, 245-64.
Haijema, B.J., Volders, H. & Rottier, P.J.M. 
Switching species tropism: an effective way to 
manipulate the feline coronavirus genome. Journal 
of Virology 2003, 77, 4528 ­ 38.
Kuo L, Godeke GJ, Raamsman MJ, Masters PS and 
Rottier PJ. Retargeting of coronavirus by 
substitution of the spike glycoprotein 
ectodomain: crossing the host cell species 
barrier. J. Virol. 2000, 74, 1393-1406.
Evans S, Cavanagh D and Britten P. Utilizing 
fowlpox virus recombinants to generate defective 
RNAs of the coronavirus infectious bronchitis 
virus. J. Gen. Virol. 2000, 81, 2855-65.
Tubolya T, Yub W, Baileyb A, Degrandisc S, Dub S, 
Erickson L and Nagya EÂ. Immunogenicity of 
porcine transmissible gastroenteritis virus spike 
protein expressed in plants.Vaccine 2000, 18, 
2023-8. Prodigene, 
http://www8.techmall.com/techdocs/TS000215-6.html Sept 2001.
"Pharmageddon" by Mae-Wan Ho, Science in Society 2003, 17 , 23-4.


This article can be found on the I-SIS website at 
http://www.i-sis.org.uk/SAGE.php

The Institute of Science in Society, PO Box 32097, London NW1 OXR
telephone: [44 20 8643 0681]   [44 20 7383 3376]   [44 20 7272 5636]

General Enquiries [log in to unmask] - 
Website/Mailing List [log in to unmask] - 
ISIS Director [log in to unmask]
MATERIAL IN THIS EMAIL MAY BE REPRODUCED IN ANY 
FORM WITHOUT PERMISSION, ON CONDITION THAT IT IS 
ACCREDITED ACCORDINGLY AND CONTAINS A LINK TO http://www.i-sis.org.uk/ 

Top of Message | Previous Page | Permalink

Advanced Options


Options

Log In

Log In

Get Password

Get Password


Search Archives

Search Archives


Subscribe or Unsubscribe

Subscribe or Unsubscribe


Archives

January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004
November 2004
October 2004
September 2004
August 2004
July 2004
June 2004
May 2004
April 2004
March 2004
February 2004
January 2004
December 2003
November 2003
October 2003
September 2003
August 2003
July 2003
June 2003
May 2003
April 2003
March 2003
February 2003
January 2003
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
December 2001
November 2001
October 2001
September 2001
August 2001
May 2001
March 2001
February 2001
January 2001
December 2000
November 2000
October 2000
September 2000
August 2000
July 2000
May 2000
April 2000
March 2000
February 2000
January 2000
December 1999
November 1999
October 1999
September 1999
August 1999
July 1999
June 1999
May 1999
April 1999
March 1999
February 1999
January 1999
December 1998
November 1998
September 1998
August 1998
July 1998
June 1998
May 1998

ATOM RSS1 RSS2



LIST.UVM.EDU

CataList Email List Search Powered by the LISTSERV Email List Manager